Page 41 - GlaxoSmithKline Pharmaceuticals AR 2012

37
Rupees
in lakhs
Previous year
Rupees
in lakhs
c. CASH FLOW FROM FINANCING ACTIVITIES
Repayments of borrowings .. .. .. .. .. .. (31.19) (25.67)
Interest paid .. .. .. .. .. .. .. (33.42) (61.21)
Dividend paid .. .. .. .. .. .. .. (378,15.44) (337,66.77)
Tax on distributed profit .. .. .. .. .. .. (58,26.53) (53,28.28)
Net cash used in financing activities .. .. .. .. C (437,06.58) (391,81.93)
Net increase in cash and cash equivalents .. .. .. .. (A+B+C) (236,01.35) 298,21.96
Cash and cash equivalents as at 1st January, 2012 (opening balance) .. 373,08.44 74,86.48
Cash and cash equivalents as at 31st December, 2012 (closing balance) .. 137,07.09 373,08.44
Net increase / (decrease) in cash and cash equivalents .. .. (236,01.35) 298,21.96
NOTES:
1. Cash and cash equivalents include:
Cash on hand .. .. .. .. .. .. 3.95 3.72
Cheques on hand .. .. .. .. .. .. 13,70.52 —
Term deposits with original maturity period of less than three months .. 56,08.00 321,46.00
Balances with banks .. .. .. .. .. .. 50,45.13 37,84.49
Unpaid dividend accounts .. .. .. .. .. 16,75.31 13,74.40
Unrealised (loss) / gain .. .. .. .. .. 4.18 (0.17)
Total cash and cash equivalents .. .. .. .. 137,07.09 373,08.44
2. Other Bank balances include:
Term deposits with original maturity period of more than three months .. 1901,75.00 1611,00.00
3. The Cash Flow Statement has been prepared under the "Indirect Method" as set out in Accounting Standard-3 on Cash Flow
Statements, notified under sub-section (3C) of Section 211 of the Companies Act, 1956.
Cash Flow Statement (Contd.)
This is the Cash Flow Statement referred to in our report of even date
For Price Waterhouse & Co., Bangalore
Firm Registration No. 007567S
Chartered Accountants
Asha Ramanathan
Partner
Membership No. 202660
For and on behalf of the Board
Vice-Chairman V. Thyagarajan
Managing Director Dr. H. B. Joshipura
Senior Executive Director M. B. Kapadia
Company Secretary A. A. Nadkarni
Mumbai, 19th February, 2013 Mumbai, 19th February, 2013
GlaxoSmithKline Pharmaceuticals Limited